SynthesisInflammopharmacology2026
Curcumin as a multi-target therapy for osteoarthritis in rats: a systematic review and meta-analysis.
Synthesis in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteoarthritis (OA) represents a significant unmet clinical need, where current management strategies primarily alleviate symptoms but fail to halt disease progression and are often associated with adverse effects. Curcumin, a natural polyphenol, has emerged as a promising therapeutic candidate. To systematically evaluate its efficacy and mechanisms, we conducted a systematic review and meta-analysis of studies from databases including PubMed, Web of Science, CNKI, and Wanfang up to October 2025. Nineteen preclinical studies meeting the inclusion criteria were analyzed. The results demonstrated that curcumin significantly improved OARSI scores (MD = - 3.36), knee diameter (SMD = - 4.40), paw withdrawal threshold (MD = 4.36), and reduced apoptotic chondrocytes (SMD = - 9.50). Mechanistically, it enhanced antioxidant defense via SOD activity (SMD = 5.17) and suppressed the TLR4/NF-κB pathway, reducing key upstream signaling mediators (TLR4: SMD = - 1.41; NF-κB: SMD = - 3.72) and downstream pro-inflammatory cytokines (TNF-α: SMD = - 3.37; IL-6: SMD = - 10.19). Furthermore, it preserved cartilage metabolism by increasing type II collagen (SMD = 2.00) and decreasing MMP-13 (SMD = - 3.51) and COMP (SMD = - 2.95). These findings indicate that curcumin exerts multi-target protective effects in OA by mitigating oxidative stress, suppressing the TLR4/NF-κB inflammatory pathway, and reducing cartilage degradation, providing a theoretical foundation for its clinical translation. Future research employing standardized methodologies will be crucial to fully elucidate the mechanistic basis of curcumin's action and optimize its therapeutic potential for clinical applications.
Indexed as
Identifiers
42258027What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.